In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16INK4A-defective, pRb-positive human melanoma cells

Journal of Cellular Physiology
Douglas M NoonanMarco G Paggi

Abstract

The cell cycle regulatory pathway responsible for the control of the late-G1 checkpoint is found recurrently altered in human malignant melanoma, often due to lack of functional p16 or pRb (pRb-1) proteins. Here we examined the ability of p16-derived peptides to mimic p16 function in two exemplary human melanoma cell lines: the p16-defective, pRb-positive A375M cells and p16-positive, pRb-defective A2058 cells. The synthetic p16-mimicking peptides strongly induced apoptosis in p16-, pRb+ A375M cells in vitro, while they had significantly less activity on p16+, pRb- A2058 cells. The most active p16-mimicking peptide, p16-AP9, also potently inhibited in vivo growth of the A375M melanoma. Treated tumors showed a threefold smaller volume (P < 0.025) and a significant reduction of the mitotic index and of PCNA expression. Growth of A2058 cells in vivo was not affected by treatment with the p16-mimicking peptide. Our results demonstrate that p16-mimicking peptides can induce apoptosis in vitro and that can inhibit tumor growth in vivo in p16-defective, pRb-expressing human melanoma cells, suggesting that p16-mimicking peptides can represent a promising tool for targeted therapy in selected cancer phenotypes.

References

Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·W E MercerS J Ullrich
Jan 28, 1986·Biochemistry·H K KleinmanG R Martin
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·G J TodaroJ E De Larco
Nov 1, 1995·Journal of Cellular Biochemistry·A BaldiA Giordano
Mar 18, 1996·Biochimica Et Biophysica Acta·G I Shapiro, B J Rollins
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W H Liggett, D Sidransky
Nov 21, 1998·Biochimica Et Biophysica Acta·M Ruas, G Peters
Jan 7, 2000·Biochemical and Biophysical Research Communications·R T Radulescu, G Jaques
Mar 10, 2001·Experimental Cell Research·J W Rocco, D Sidransky
Mar 21, 2002·Journal of the National Cancer Institute·Elena V SviderskayaDorothy C Bennett
Jun 6, 2003·Oncogene·Nicholas K Hayward
Jun 6, 2003·Oncogene·E Sharpless, Lynda Chin

❮ Previous
Next ❯

Citations

Jun 29, 2007·The Journal of Investigative Dermatology·William K KaufmannNorman E Sharpless
Jan 9, 2008·Journal of Cellular Physiology·Hong ZhangStanley N Cohen
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·P Seshidhar ReddyDe-Chao Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis